RxDoctor Payments Data

Pamela Ramirez Stroman, MD

Family Medicine · Weslaco, TXNPI 1669630752

Payments from drug & device makers

$1,348in general payments, 2019–2025

Across 64 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Romark Laboratories, LC$850
  • Mylan Specialty L.p.$105
  • Novo Nordisk$78
  • Boehringer Ingelheim$63
  • Lilly USA, LLC$45
  • Abbott$42
  • plus $165 from 7 others

What the payments were for

  • Food & beverage$1,348100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,348 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$69,039
Medicare patients
106
Services billed
1,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide71$90,448
TrulicityDulaglutide24$30,160
FarxigaDapagliflozin Propanediol22$22,924
JardianceEmpagliflozin11$18,531
SynjardyEmpagliflozin/Metformin Hcl16$13,951
JanuviaSitagliptin Phosphate19$12,047
MyrbetriqMirabegron21$10,217
TradjentaLinagliptin15$10,029
Breo ElliptaFluticasone/Vilanterol12$5,369
Ezetimibe14$1,417
Rosuvastatin Calcium62$1,079
Hydrocodone-IbuprofenHydrocodone/Ibuprofen12$887
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen55$856
Duloxetine Hcl25$719
Losartan Potassium57$648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$45$120,60795 claims
Boehringer IngelheimJardiance, Synjardy, Tradjenta$63$42,51142 claims
AstraZenecaFarxiga$38$22,92422 claims
Astellas Pharma US IncMyrbetriq$16$10,21721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Weslaco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →